CorMedix Past Earnings Performance
Past criteria checks 0/6
CorMedix's earnings have been declining at an average annual rate of -5.6%, while the Pharmaceuticals industry saw earnings growing at 1.7% annually. Revenues have been declining at an average rate of 44.2% per year.
Key information
-5.6%
Earnings growth rate
14.3%
EPS growth rate
Pharmaceuticals Industry Growth | 6.0% |
Revenue growth rate | -44.2% |
Return on equity | -66.1% |
Net Margin | n/a |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
We Think CorMedix (NASDAQ:CRMD) Can Afford To Drive Business Growth
Apr 06We're Hopeful That CorMedix (NASDAQ:CRMD) Will Use Its Cash Wisely
Nov 02Here's Why We're Not Too Worried About CorMedix's (NASDAQ:CRMD) Cash Burn Situation
Jul 31CorMedix (NASDAQ:CRMD) Is In A Good Position To Deliver On Growth Plans
Feb 25FDA again rejects CorMedix's application for lead candidate DefenCath, shares sink ~60%
Aug 08Here's Why We're Not Too Worried About CorMedix's (NASDAQ:CRMD) Cash Burn Situation
Jul 16We're Hopeful That CorMedix (NASDAQ:CRMD) Will Use Its Cash Wisely
Mar 01Here's Why We're Not Too Worried About CorMedix's (NASDAQ:CRMD) Cash Burn Situation
Sep 09CorMedix Inc.'s (NASDAQ:CRMD) Intrinsic Value Is Potentially 58% Above Its Share Price
Feb 11We're Hopeful That CorMedix (NYSEMKT:CRMD) Will Use Its Cash Wisely
Jan 04Revenue & Expenses BreakdownBeta
How CorMedix makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 0 | -46 | 36 | 13 |
30 Sep 23 | 0 | -40 | 28 | 14 |
30 Jun 23 | 0 | -37 | 25 | 13 |
31 Mar 23 | 0 | -33 | 23 | 12 |
31 Dec 22 | 0 | -30 | 20 | 11 |
30 Sep 22 | 0 | -29 | 19 | 11 |
30 Jun 22 | 0 | -31 | 18 | 13 |
31 Mar 22 | 0 | -28 | 16 | 13 |
31 Dec 21 | 0 | -28 | 16 | 13 |
30 Sep 21 | 0 | -27 | 16 | 12 |
30 Jun 21 | 0 | -25 | 15 | 10 |
31 Mar 21 | 0 | -24 | 15 | 14 |
31 Dec 20 | 0 | -22 | 14 | 13 |
30 Sep 20 | 0 | -21 | 13 | 14 |
30 Jun 20 | 0 | -47 | 12 | 13 |
31 Mar 20 | 0 | -44 | 11 | 11 |
31 Dec 19 | 0 | -44 | 10 | 11 |
30 Sep 19 | 0 | -36 | 9 | 4 |
30 Jun 19 | 1 | -14 | 9 | 10 |
31 Mar 19 | 1 | -22 | 8 | 13 |
31 Dec 18 | 0 | -27 | 8 | 19 |
30 Sep 18 | 0 | -39 | 8 | 32 |
30 Jun 18 | 0 | -39 | 8 | 29 |
31 Mar 18 | 0 | -36 | 8 | 28 |
31 Dec 17 | 0 | -33 | 9 | 24 |
30 Sep 17 | 0 | -29 | 9 | 20 |
30 Jun 17 | 0 | -28 | 9 | 21 |
31 Mar 17 | 0 | -28 | 9 | 19 |
31 Dec 16 | 0 | -25 | 9 | 16 |
30 Sep 16 | 0 | -22 | 9 | 13 |
30 Jun 16 | 0 | -18 | 9 | 8 |
31 Mar 16 | 0 | -17 | 10 | 7 |
31 Dec 15 | 0 | -18 | 10 | 6 |
30 Sep 15 | 0 | -17 | 10 | 5 |
30 Jun 15 | 0 | -17 | 8 | 4 |
31 Mar 15 | 0 | -9 | 8 | 2 |
31 Dec 14 | 0 | -21 | 7 | 1 |
30 Sep 14 | 0 | -22 | 7 | 1 |
30 Jun 14 | 0 | -19 | 6 | 1 |
31 Mar 14 | 0 | -25 | 5 | 1 |
31 Dec 13 | 0 | -10 | 3 | 1 |
30 Sep 13 | 0 | -7 | 2 | 2 |
Quality Earnings: CRMD is currently unprofitable.
Growing Profit Margin: CRMD is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CRMD is unprofitable, and losses have increased over the past 5 years at a rate of 5.6% per year.
Accelerating Growth: Unable to compare CRMD's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CRMD is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-6.8%).
Return on Equity
High ROE: CRMD has a negative Return on Equity (-66.06%), as it is currently unprofitable.